<DOC>
	<DOCNO>NCT02904876</DOCNO>
	<brief_summary>Through phase IV study , multicenter prospective exploratory , uncontrolled , investigator propose identify MRI predictive factor treatment response , use diffusion MRI sequence , addition conventional sequence . The primary objective study link change MRI diffusion response treatment Tysabri 2 year . The secondary objective compare evolution diffusion MRI data volumetric MRI data .</brief_summary>
	<brief_title>Evaluation Early Changes Visible Diffusion MRI Response Two Years Treatment With Tysabri Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Major Patient Patient relapse remit multiple sclerosis eligible treatment Tysabri Patient affiliate social security scheme Patient sign informed consent Patient inform result prior medical examination Patient currently eligible treatment Tysabri Contraindication MRI scan Unability provide inform consent ( subject emergency situation , difficulty understanding , ... ) Patient judicial protection Patient guardianship curatorship Pregnancy ( woman childbearing age absence effective contraception ) Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>